Αποτελέσματα Αναζήτησης
This review focuses on the pathology, causes, risk factors, symptoms, prevalence data, symptomatic treatments, and new research aimed at possible preventions and/or treatments of mitochondrial diseases.
This review is aimed at a general medical and neurologist readership and provides a clinical approach to the recognition, investigation, and treatment of mitochondrial myopathies. Emphasis is placed on practical management considerations while including some recent updates in the field.
Topics of discussion include an overview of bone biology and epidemiology; the clinical use of bone densitometry, spine x-rays, and markers of bone turnover; laboratory evaluation for secondary causes of osteoporosis; basic principles of nutrition and exercise for patients with osteoporosis; current therapeutic options; glucocorticoid-induced os...
14 Φεβ 2024 · We performed a retrospective chart review of adult patients diagnosed with mitochondrial myopathy at Mayo Clinic (2005–21). We identified 94 patients. Median time from symptom onset to diagnosis was 11 years (interquartile range 4–21 years). Median age at diagnosis was 48 years (32–63 years).
In the past few years, medications emerged to help patients with mitochondrial diseases, Elemipretide for myopathy in general and deoxycytidine (dC) + deoxythymidine (dT) for TK2 deficiency. Gene therapy is a promise for future treatments. Physical conditioning was proved to improve mitochondrial myopathy symptoms.
12 Ιουν 2024 · Mitochondrial disease results from failure of mitochondria to function properly. This can lead to less energy, cell injury and cell death. The most common organs that may experience damage are the brain, heart, liver, muscles, kidneys and the endocrine system.
Both nonpharmacological therapy (calcium and vitamin D supplementation, weight-bearing exercise, and fall prevention) and pharmacological treatments (antiresorptive and anabolic agents) may be helpful in the prevention and treatment of osteoporosis.
